168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
14 citations
,
June 2021 in “Expert Opinion on Therapeutic Patents” New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
23 citations
,
March 1994 in “Fertility and sterility” Most patients improved with oral contraceptives, but some needed additional treatment.
August 2002 in “Inpharma Weekly”
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
February 2023 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Microneedling with triamcinolone is a safe, effective, and less painful treatment for alopecia areata.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
August 1946 in “Journal of the American Medical Association” Companies agreed to stop making false health claims about their products.
10 citations
,
November 2018 in “Nature Biotechnology” Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.
November 2024 in “Journal of the American Academy of Dermatology”
22 citations
,
November 2011 in “Journal of Analytical Toxicology” Scientists have developed a new method to detect steroid abuse in athletes using cell-based tests, which could be the future of anti-doping methods.
April 2026 in “Regenerative Medicine” Significant progress and investment in advanced therapies and regenerative medicine continue.
A new topical treatment using micelles shows promise for safer and more effective hair regrowth in androgenetic alopecia.
April 2024 in “Bioactive materials” New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
21 citations
,
May 2024 in “Journal of Ethnopharmacology”
14 citations
,
August 2009 in “Cancer epidemiology” AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
9 citations
,
January 2017 in “Organic Process Research & Development” In 2017, a new method was created to efficiently produce a topical antiandrogen, a compound used to treat excess sebum and acne, with a high yield and purity.
May 2026 in “BMC Medicine” ACOD1 deficiency worsens hair loss by causing cell aging and mitochondrial problems, but 4-OI may help.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
3 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.